Home › Hereditary Angioedemas › NCT07428499

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Have a documented diagnosis of HAE (Type I or II)
* Completed Study ADX-324-301
* Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)

Exclusion Criteria:

* A negative reaction to study drug in ADX-324-301

About the study

Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.

What is being tested

• ADX-324 Dose Level 1 (drug)
• ADX-324 Dose Level 2 (drug)

Sponsor: ADARx Pharmaceuticals, Inc. · Participants: 90 · Started: Apr 2, 2026

Contact the study team

• Lupe Gallegos · Phone: 877-232-7974

Official record on ClinicalTrials.gov — NCT07428499

Locations in the U.S.

Conditions

• Hereditary Angioedemas

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.